Asymmetric dimethylarginine
Heart and Muscle Health
This panel includes biomarkers used to evaluate heart function, heart muscle injury, skeletal muscle damage, and vascular health. These markers help clinicians investigate symptoms such as chest pain, shortness of breath, fatigue, or muscle weakness, and can support the diagnosis or monitoring of heart failure, heart attacks, muscle disorders, and cardiovascular risk.
The biomarkers in this panel fall into four main clinical groups.
Heart Failure and Cardiac Stress Markers
These biomarkers are released when the heart is under increased pressure or strain, such as in heart failure or ventricular dysfunction.
B-Type Natriuretic Peptide (BNP)
BNP is a hormone released by the heart’s ventricles when they are stretched due to increased blood volume or pressure. Elevated BNP levels are commonly used to diagnose and monitor heart failure and assess the severity of cardiac stress.
NT-proBNP
NT-proBNP is an inactive fragment released alongside BNP when the heart is under strain. It is widely used as a sensitive biomarker for heart failure and can help distinguish heart-related causes of shortness of breath from lung or other conditions.
Galectin-3
Galectin-3 is associated with cardiac fibrosis and remodeling, processes that occur as heart failure progresses. It is often used to help assess heart failure prognosis and disease progression.
Cardiac Injury Markers (Heart Attack Indicators)
These biomarkers are released when heart muscle cells are damaged, such as during a heart attack or other forms of cardiac injury.
Troponin
Troponin proteins are released into the bloodstream when heart muscle cells are injured. Elevated troponin levels are one of the most important markers used to diagnose myocardial infarction (heart attack).
Troponin T, High Sensitivity
High-sensitivity troponin tests detect even very small amounts of heart muscle injury, allowing earlier detection of cardiac stress or damage.
CK-MB
CK-MB is a form of creatine kinase found primarily in the heart muscle. Elevated levels can indicate damage to cardiac tissue, although troponin tests are now used more frequently for diagnosing heart attacks.
MB Relative Index
The MB relative index compares CK-MB levels with total CK levels to help determine whether muscle damage is cardiac or skeletal in origin.
Skeletal Muscle Damage Markers
These biomarkers help identify muscle injury, inflammation, or muscle disease affecting the skeletal muscles.
Creatine Kinase (CK)
Creatine kinase is an enzyme found in skeletal muscle, heart muscle, and brain tissue. Elevated levels often indicate muscle injury, inflammation, or intense physical activity.
Creatine Phosphokinase (CPK)
CPK is another name for creatine kinase and is commonly measured to evaluate muscle damage or heart injury.
CK-MM
CK-MM is the creatine kinase subtype found mainly in skeletal muscle and is commonly elevated in muscle trauma, strenuous exercise, or muscle disorders.
CK-BB
CK-BB is primarily found in brain tissue and smooth muscle, although small amounts may appear in the bloodstream in certain medical conditions.
Aldolase
Aldolase is an enzyme involved in glucose metabolism. Elevated levels may occur in muscle diseases such as polymyositis, dermatomyositis, and muscular dystrophy.
Vascular Function and Cardiovascular Risk Markers
These biomarkers provide insight into endothelial function and cardiovascular risk, particularly in relation to nitric oxide metabolism and vascular health.
ADMA (Asymmetric Dimethylarginine)
ADMA inhibits nitric oxide production and is associated with endothelial dysfunction, an early contributor to atherosclerosis and cardiovascular disease.
SDMA (Symmetric Dimethylarginine)
SDMA is related to kidney function and nitric oxide metabolism. Elevated levels may indicate reduced renal clearance and increased cardiovascular risk.
Other Enzyme Variants
Macro CK Type 1
Macro CK Type 1 is an atypical form of creatine kinase that may appear in the blood when CK binds to certain proteins. It can sometimes cause persistently elevated CK levels without true muscle injury.
Macro CK Type 2
Macro CK Type 2 is a mitochondrial form of creatine kinase that may appear in certain serious illnesses or tissue damage.
Biomarkers in this category
18 biomarkers · optimal ranges shown
Glycolytic enzyme
plays an important role in regulating the circulation
found mostly in brain tissue and raised in brain injury
found mostly in the heart muscle and raised in myocardial infarction
found mostly in skeletal muscles and raised in muscular injuries
Muscle enzyme measuring tissue damage in heart, skeletal muscle, or brain.
measures a heart-specific enzyme to diagnose heart damage
When a muscle is damaged, CPK leaks into the bloodstream.
Aiding in the prognosis for people diagnosed with heart failure
The relative index represents the ratio of CKMB to the CK, total. Relative index = CK-MB, in ng/mL ÷ CK, total, U/L x 100. Due to the different units measured (ng/mL for CK-MB vs. U/L for CK, total), this does not represent a true percentage and is, therefore, called a “relative index.” Currently, a relative index of ≥5.0% suggests the MB may be myocardial in origin. The relative index may be of particular value in patients who have an elevated CK, total due to trauma or surgery. Both an elevated CK-MB and Relative Index are suggestive of Myocardial Infarction.
released in response to changes in pressure inside the heart.
released in response to changes in pressure inside the heart.
ADMA/SDMA may be measured in individuals with multiple risk factors for the development of CVD. SDMA is primarily excreted in the urine and identifies reduced renal function. One of the earliest manifestations of endothelial dysfunction is nitric oxide (NO) deficiency, which promotes atherosclerosis. Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), its structural isomer, are metabolites of L-arginine, an amino acid that is catalyzed to L-citrulline and NO by nitric oxide synthase (NOS). Both ADMA and SDMA have distinct pathophysiologies and manifestations. ADMA is a competitive inhibitor of NOS thereby reducing NO production and promoting endothelial dysfunction. SDMA also interferes with NO production, but does so indirectly by reducing the cellular availability of arginine. ADMA is primarily cleared through enzymatic degradation in the bloodstream and its presence identifies subclinical cardiovascular disease (CVD). Conversely, SDMA is primarily excreted in the urine and identifies reduced renal function. Interpretation: ADMA: Low // SDMA: Low Normal endothelial function Med High Low ADMA: Med / High // SDMA: Low Endothelial dysfunction and possible presence of pre-diabetes/diabetes or CVD ADMA: Low // SDMA: High Reduced renal function ADMA: Med / High // SDMA: High - Endothelial dysfunction and possible presence of pre-diabetes/diabetes or CVD - Reduced renal function References: American Diabetes Association Professional Practice Committee; 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022. Diabetes Care 1 January 2022; 45 (Supplement_1): S125–S143. https://doi.org/10.2337/dc22-S009
Troponin proteins are released when the heart muscle has been damaged, such as occurs with a heart attack.
Heart muscle injury marker